Research programme: antigen inserted alpha virus like particle vaccines - VLP Therapeutics

Drug Profile

Research programme: antigen inserted alpha virus like particle vaccines - VLP Therapeutics

Alternative Names: iα-VLP - VLP Therapeutics; VLPM01

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VLP Therapeutics
  • Developer Georgetown University; Institute of Tropical Medicine, Nagasaki University; VLP Therapeutics
  • Class Cancer vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malaria
  • Research Autoimmune disorders; Cancer; Dengue; Infections

Most Recent Events

  • 13 Oct 2017 VLP Therapeutics receives Small Business Innovation Research grant from National Cancer Institute, USA for vaccine-based immunotherapy development in Cancer
  • 05 Oct 2016 VLP Therapeutics receives grant from Global Health Innovative Technology Fund for Dengue vaccine development in Japan
  • 14 Jul 2016 VLP Therapeutics receives Peer Reviewed Medical Research Program Technology/Therapeutic Development grant from the United States Department of Defense for Malaria vaccine development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top